Lena Winstedt - Publications

Imlifidase enables AAV gene therapy in a seropositive Crigler-Najjar patient: On the verge of a paradigm shift.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 02, 2026

Imlifidase-generated Single-cleaved IgG: Implications for Transplantation.

Journal: Transplantation

Published: December 30, 2021

Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes).

Journal: Transplantation

Published: October 23, 2020

Streptococcus pyogenes Infection and the Human Proteome with a Special Focus on the Immunoglobulin G-cleaving Enzyme IdeS.

Journal: Molecular & cellular proteomics : MCP

Published: December 04, 2017

Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: October 13, 2017

IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation.

Journal: The New England journal of medicine

Published: August 03, 2017

Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy.

Journal: Molecular cancer therapeutics

Published: February 01, 2017

IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barré syndrome.

Journal: Experimental neurology

Published: December 04, 2016

The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: August 28, 2015

Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity.

Journal: PloS one

Published: November 24, 2014

A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours.

Journal: British journal of cancer

Published: February 16, 2012